The US FDA has approved ramipril oral solution, an angiotensin-converting enzyme (ACE) inhibitor, for the treatment of hypertension in adults to lower blood pressure (BP), and thereby decrease the risk of fatal and non-fatal cardiovascular events, particularly strokes and myocardial infarctions (MI). It is also indicated for patients aged 55 years and above, who are at high risk of major cardiovascular events, to reduce the likelihood of MI, stroke, or death from cardiovascular causes. Additionally, in adults with post-MI heart failure (HF), ramipril is indicated to lower the risk of cardiovascular death and HF-related hospitalizations.
Clinical evidence Single-dose studies demonstrated that ramipril begins to lower BP within 1–2 hours, reaching maximum reduction between 3–6 hours after administration. Its antihypertensive effect was sustained for up to 24 hours. In longer-term studies…
